Stock CERO CERO THERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials CERo Therapeutics Holdings, Inc.

Equities

CERO

US71902K1051

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
1.38 USD 0.00% Intraday chart for CERo Therapeutics Holdings, Inc. -2.13% -87.45%
Apr. 02 CERo Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 11 Top Premarket Decliners MT

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 222.6 236 68.71
Enterprise Value (EV) 1 221.5 236.2 70.17
P/E ratio - -346 x -28.3 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA - - -
EV / FCF - -17,568,677 x 13,719,411 x
FCF Yield - -0% 0%
Price to Book -29.7 x -6.46 x -4.84 x
Nbr of stocks (in thousands) 22,458 22,981 6,246
Reference price 2 9.910 10.27 11.00
Announcement Date 3/24/22 3/24/23 4/2/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023
Net sales - - -
EBITDA - - -
EBIT 1 -0.5692 -2.905 -2.933
Operating Margin - - -
Earnings before Tax (EBT) 1 -0.5699 -0.0686 -2.441
Net income 1 -0.5409 -0.6677 -2.536
Net margin - - -
EPS - -0.0297 -0.3885
Free Cash Flow - -13.44 5.114
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 3/24/22 3/24/23 4/2/24
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023
Net Debt 1 - 0.17 1.46
Net Cash position 1 1.1 - -
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -13.4 5.11
ROE (net income / shareholders' equity) - 7.25% 20.1%
ROA (Net income/ Total Assets) - -1.63% -7.2%
Assets 1 - 40.9 35.23
Book Value Per Share 2 -0.3300 -1.590 -2.270
Cash Flow per Share 2 0.0500 0.0700 0.0200
Capex - - -
Capex / Sales - - -
Announcement Date 3/24/22 3/24/23 4/2/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CERO THERAPEUTICS HOLDINGS, INC. Stock CERo Therapeutics Holdings, Inc.
-87.45% 20.32M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 97.47B
ARGENX SE Stock argenx SE
+5.71% 22.25B
BIONTECH SE Stock BioNTech SE
-12.60% 21.68B
GENMAB A/S Stock Genmab A/S
-9.70% 18.2B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.02B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.37B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CERO Stock
  4. Financials CERo Therapeutics Holdings, Inc.